Active	Status	Sponsor type	Region	Phase	Filter
10 Active 5 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Merrill, Joan T
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus	Terminated	2	9	US	Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin	National Institute of Allergy and Infectious Diseases (NIAID)	Systemic Lupus Erythematosus	04/24	04/24
NAIVE, NCT04726553: Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE	Recruiting	1	20	US	Anifrolumab, Medi 546, Standard of Care, azathioprine, methotrexate, mycophenolate mofetil, corticosteroids, antimalarials	Oklahoma Medical Research Foundation, NYU Langone Health, Yale University, Piedmont Heart Institute, Inc., Atlanta, GA, Columbia University	Systemic Lupus Erythematosus (SLE)	12/23	12/24
Kamath, Shruti
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis	Recruiting	2	74	US	VIB4920, Placebo for VIB4920	National Institute of Allergy and Infectious Diseases (NIAID)	Lupus Nephritis	08/26	03/27
Ko, Kichul
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis	Recruiting	2	74	US	VIB4920, Placebo for VIB4920	National Institute of Allergy and Infectious Diseases (NIAID)	Lupus Nephritis	08/26	03/27
Usman, Sabeena
SIRIUS-SLE 2, NCT05624749 / 2022-002690-29: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus	Recruiting	3	280	Europe, US, RoW	ianalumab, VAY736, placebo	Novartis Pharmaceuticals, Novartis Pharma AG	Systemic Lupus Erythematosus	01/27	01/29
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus	Terminated	2	9	US	Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin	National Institute of Allergy and Infectious Diseases (NIAID)	Systemic Lupus Erythematosus	04/24	04/24
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis	Recruiting	2	74	US	VIB4920, Placebo for VIB4920	National Institute of Allergy and Infectious Diseases (NIAID)	Lupus Nephritis	08/26	03/27
Yadav, Sudeep
MINT, NCT05799755: Myositis Interstitial Lung Disease Nintedanib Trial	Active, not recruiting	4	70	US	Nintedanib, OFEV, Placebo, Standard of Care	Rohit Aggarwal, MD, Boehringer Ingelheim	Myositis Associated Interstitial Lund Disease (MA-ILD)	07/25	12/25
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis	Recruiting	2	74	US	VIB4920, Placebo for VIB4920	National Institute of Allergy and Infectious Diseases (NIAID)	Lupus Nephritis	08/26	03/27
Sheetal, Desai
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis	Recruiting	2	74	US	VIB4920, Placebo for VIB4920	National Institute of Allergy and Infectious Diseases (NIAID)	Lupus Nephritis	08/26	03/27